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A group of 105 women (54 of whom were, and had only ever been, taking valproate for at least a year, and 51 who had only
ever taken either lamotrigine or carbamazepine, for at least a year) were compared with a group of 50 women who did not
have epilepsy: any oral contraceptive taken at the time of testing was recorded and blood levels of follicle stimulating hormone
(FSH), luteinising hormone (LH), testosterone and prolactin were estimated from days 2 to 6 of the menstrual cycle (day 1
being the first day of bleeding) and an MRI scan made of their pelvis. Women with epilepsy in general were significantly more
likely to exhibit evidence on MRI scanning, of polycystic ovaries (PCO): women taking valproate but not an oral contraceptive
were significantly more likely to have clinical biochemical evidence of the polycystic ovarian syndrome (PCOS) with raised LH
and/or testosterone levels between days 2 and 6 of their menstrual cycle than women who did not have epilepsy: this was not so
for women taking lamotrigine or carbamazepine. Since the polycystic ovary syndrome has potentially serious consequences it
is suggested that, where possible, valproate is avoided in women of child bearing potential.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
There is a great deal of controversy about whether or
not women with epilepsy of child bearing age differ
from women who do not have epilepsy. There seems
little doubt that women with epilepsy, if other factors
are taken into account, have a significantly lower fer-
tility rate than women without epilepsy and possibly,
therefore, some factor to account for it1. But if this is
so (and the study that showed it was sturdy and re-
liable and generally believed) the explanation, so far,
escapes us.
Could the explanation lie in the effect of epilepsy
on the menstrual cycle itself? There is some confus-
ing evidence for this2. Or could the explanation lie in
the effect of various anticonvulsants on the menstrual
cycle? There is some even more confusing evidence
that this may (or may not) be so, reviewed from a gy-
naecological perspective in an accompanying article2.
The evidence here is even more confusing: some of the
reasons, but not all, are described in the accompanying
paper2. Others have been discussed elsewhere3. For a
general review of the current beliefs on the relationship
between ovarian structure and function and epilepsy
see our previous paper in Seizure3 and the best prac-
tice guidelines on managing women with epilepsy4.
The question to be determined is whether there is
any good evidence that epilepsy itself affects the men-
strual cycle or leads to an increased incidence of men-
strual irregularity or whether medication used to treat
epilepsy might do this. The evidence is conflicting,
and both epilepsy itself and its treatment may well do
so3. In particular, one anticonvulsant drug, sodium val-
proate, has been suggested to increase the incidence
of both polycystic ovaries (PCO) and the polycystic
ovary syndrome (PCOS)5–7. However, there is much
wrong with these studies. They are difficult to under-
stand and, particularly in the last study, the numbers
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are small: there is a strong possibility of bias, particu-
larly in the valproate group and not all of the patients
had only ever taken just one anticonvulsant drug. Cer-
tainly other studies (reviewed by Reference 2) do not
support the view that valproate is particularly associ-
ated with polycystic ovaries or the polycystic ovary
syndrome (since the two are not the same). However,
to be certain (since the suspicion remains that val-
proate may be associated with the polycystic ovary
syndrome or polycystic ovaries) further evidence is
needed in a study which tries, as far as possible, to
control for or obviate the various factors that go to
make up the polycystic ovary syndrome.
First of all, what is meant by polycystic ovaries, and
the polycystic ovary syndrome? Here we run into an
immediate difficulty. The terms are used differently in
Europe and the United States (and ‘polyfollicular’ is
sometimes used instead of ‘polycystic’ in Europe—
we happen to think more correctly8). A polycystic
(or polyfollicular) ovary is detected by scanning (usu-
ally by ultrasound—although MRI is probably more
accurate—see References 3, 9). Therefore, if scanning
is not part of the investigation—as is often the case in
the States—the term polycystic ovary becomes mean-
ingless. In Europe, a polycystic ovary is arbitrarily de-
fined as one which has 10 or more cysts visible on
scanning (so, for instance, an ovary with 9 cysts is not
polycystic whereas an ovary with 10, is). The other
factor is, of course, time: one may have polycystic
ovaries 1 month, and normal ones the next, as some
cysts disappear. So the term is rather arbitrary: the im-
portant thing is that apart from an unusual number of
cysts the ovary is behaving normally and there are no
associated hormonal or other abnormalities8.
The polycystic ovary syndrome also has varying
definitions but implies that there is a definite hor-
monal abnormality (when measured at the right time
of the month—an important point) with sometimes
other clinical evidence of ovarian dysfunction (e.g.
weight gain, irregular periods, etc.8). However, pro-
viding there is a definite hormonal abnormality, there
do not have to be other symptoms or signs. The hor-
monal abnormalities that all experts recognise are, at
the right time in the month (1) an absolutely raised
luteinising hormone level, (2) a raised LH level com-
pared with the follicular stimulating hormone level
(reversed ratio), (3) a raised testosterone level, (4) a
consistently raised prolactin level. This last can have
other explanations and most authorities would be un-
likely to accept it on its own as due to the polycystic
ovary syndrome unless it could proved to be consis-
tent and not due to other causes8.
Levels of luteinising hormone (LH) and follicle
stimulating hormone (FSH) vary throughout the
menstrual month and so can only be considered as
abnormal if they are measured at a specific known
time. This is taken to be between days 2 and 6 of
the menstrual cycle, day 1 being the first day of
bleeding. At this easily measurable stage of the cycle
(particularly in irregular cycles) both levels are low.
Thereafter they rise, peak at ovulation and then fall
(unless pregnancy occurs)8. A high level of either
hormone measured just after menstruation starts is
abnormal8. Testosterone and prolactin levels do not
fluctuate much throughout the cycle, although testos-
terone has a diurnal variation and is best measured at
the same time of day. In women who are not menstru-
ating at all it does not matter when the blood is taken
(although it would be necessary to make sure the
woman does have persistent amenorrhoea and is not
pregnant): there are several causes of this state. Sadly,
some papers on the relationship between antiepileptic
medication and menstruation do not mention when
in the cycle the blood was taken and one is left to
presume it was taken at the right time in the month3.
In most of the papers, too, it is not always clear
whether the women are just taking the AED under
scrutiny, and had only ever taken it, or whether they
are taking other AEDs currently, or were in the past.
If one is to clearly elucidate the effect of AEDs on the
menstrual cycle it would be important to use women
who have only ever taken the one AED in question. In
addition, since they have their own effect, it is neces-
sary to determine whether the woman is currently tak-
ing an oral contraceptive or not at the time of testing.
We, therefore, determined to try to discover whether
there was a significant difference between the chem-
istry of the menstrual cycles of women who had only
ever taken valproate and women who had only ever
taken either lamotrigine or carbamazepine, but had
never taken valproate. To keep the comparison as tight
as possible we would only consider women who had
primary generalised epilepsy: although there is ev-
idence that endocrine abnormalities are common in
women with partial onset epilepsy10 they are also said
to be common in women with primary generalised
epilepsy11. Women with primary generalised epilepsy
are more likely to have only ever taken one anticon-
vulsant and are extremely unlikely to have structural
causes for their seizures, making comparison easier.
In addition 50 normal women, without epilepsy,
would be compared with the epilepsy groups. Initially
it had been hoped to compare 50 women who had
only ever taken valproate with 50 women who had
only ever taken lamotrigine, but this proved difficult
to accomplish in the 2 years given to the project so
we included ever only carbamazepine takers as well.
So we end up with three groups: those women who
are taking and have only ever taken valproate; those
who are taking and have only ever taken either lam-
otrigine or carbamazepine (there is no difference at
all between these two groups in any parameter); and
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50 normal women, who do not and who never have,
had epilepsy. All the women with epilepsy have pri-
mary generalised epilepsy and have been taking their
particular anticonvulsant for at least a year. Women
with epilepsy were obtained from new patients attend-
ing the Birmingham University Seizure Clinic situated
in the Queen Elizabeth Psychiatric Hospital in Birm-
ingham: normal women came from students and staff
of the Queen Elizabeth Psychiatric Hospital, and the
Universities of Birmingham and Aston.
From each subject (those on an anticonvulsant and
those not) blood was taken (in the morning) between
days 2 and 6 of the menstrual cycle for full blood
count, biochemical profile, thyroid function tests and
estimation of LH, FSH, testosterone and prolactin.
At the same time they had an MRI of the pelvis
at the adjacent Nuffield Centre all of which were
read and reported blind to the other data. The results
were tabulated and calculated. Those with dubious
or potentially dangerous scans were re-scanned as
needed (including ultrasound scans) and referred to
the Women’s Hospital service if necessary. No scans
turned out to be malignant in the end. We excluded
from our survey women who were not menstruating at
all: there were five potentially in the valproate group
and one in the normal group—all were excluded from
the study. The reason that more than 50 patients were
included in the two anticonvulsant groups was that, af-
ter identification, it took some time to obtain the blood
at the right time of the month in some patients, so
more patients were included in these groups than 50.
RESULTS
We first measured the prevalence of polycystic
ovaries based on MRI criteria (European definition)
in the three groups (valproate, lamotrigine or carba-
mazepine, no epilepsy; Table 1a–d).
These tables strongly suggest that the prevalence
of polycystic ovaries is significantly higher in the
epilepsy group, although within group comparison
Table 1: Normal ovaries versus PCO.
Table 1a:
N Normal % (number) PCO % (number)
VPA 54 50 (27) 50 (27)
LTG/CBZ 51 67 (34) 33 (17)
Normal 50 94 (47) 6 (3)
λ2 for three independent samples P =< 0.001. No significant
difference between VPA versus LTG/CBZ, therefore difference is
due to comparison between normal and other two groups (see
Table 1c).
Table 1b:
N Normal % PCO %
(number) (number)
VPA Pill 15 80 (12) 20 (3)
No pill 39 41 (16) 59 (23)
LTG/CBZ Pill 14 86 (12) 14 (2)
No pill 37 59 (22) 41 (15)
Normal Pill 23 91 (21) 9 (2)
No pill 27 96 (26) 4 (1)
Between groups: no significant differences between three groups
taking the OCP. λ2 for three independent samples (VPA,
LTG/CBZ, normal) in those not on OCP P =< 0.001. This again
is due to differences between epilepsy and normal (P =< 0.001
by Fisher’s Exact test). Within groups: VPA—pill versus no
pill—P = 0.001 (λ2 for two independent samples), therefore
women taking VPA have greater chance of PCO if not on OCP.
LTG/CBZ—pill versus no pill—no significant difference.
Normal—pill versus no pill—no significant difference.
Table 1c:
N Normal % (number) PCO % (number)
Epilepsy 105 58 (61) 42 (44)
Normal 50 94 (47) 6 (3)
λ2 for two independent samples (plus Fisher’s Exact test)
P =< 0.001, this suggests that women with epilepsy have
greater incidence of PCO than the normal population.
Table 1d:
N Normal % PCO %
(number) (number)
Epilepsy Pill 29 83 (24) 17 (5)
No pill 76 50 (38) 50 (38)
Normal Pill 23 91 (21) 9 (2)
No pill 27 96 (26) 4 (1)
Between groups: no significant differences between groups
taking OCP. P =< 0.001 between groups not taking OCP
(Fisher’s Exact test). Within groups: epilepsy group—pill versus
no pill—P = 0.003 (Fisher’s Exact test), therefore pill may
protect against PCO in women with epilepsy. Normal
groups—pill versus no pill—no significant difference.
suggests this is more, but not completely, in the val-
proate group; the pill may well protect women with
epilepsy from having polycystic ovaries, although, as
previously remarked, the significance of polycystic
ovaries without other evidence of ovarian dysfunction
is open to question, and is only found in the European
Classification.
We now look at the polycystic ovary syndrome de-
fined (in the American way8) as hormonal evidence of
the syndrome with, or without historical evidence of
ovarian pathology—raised LH at the right time of the
month and/or raised testosterone levels. The very rare
finding of raised prolactin on its own was not taken as
evidence of the polycystic ovary syndrome. Table 2a
suggests that the greatest proportion of the polycys-
tic ovary syndrome is to be found in the epilepsy
group whilst Table 2b confirms that taking an oral
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Table 2: Non-PCOS versus PCOS.
Table 2a:
N Non-PCOS % PCOS %
(number) (number)
VPA 54 70 (38) 30 (16)
LTG/CBZ 51 94 (48) 6 (3)
Normal 50 86 (43) 14 (7)
λ2 for three independent samples P = 0.004. VPA versus
LTG/CBZ λ2 (plus Fisher’s Exact test) P = 0.002. No significant
difference between LTG/CBZ versus normal, nor epilepsy versus
normal, so greater prevalence of PCOS probably due to VPA.
Table 2b:
N Non-PCOS % PCOS %
(number) (number)
VPA Pill 15 80 (12) 20 (3)
No pill 39 67 (26) 33 (13)
LTG/CBZ Pill 14 93 (13) 7 (1)
No pill 37 95 (35) 5 (2)
Normal Pill 23 96 (22) 4 (1)
No pill 27 77 (21) 23 (6)
Between groups: no pill—λ2 for three independent samples
P = 0.010. VPA versus LTG/CBZ P = 0.002 (λ2), therefore if
not taking pill and on VPA then have greater chance of PCOS
(Fishers = 0.003). No significant difference between epilepsy
and normal groups. Pill: no significant differences between any
groups (so pill protects in VPA group). Within groups: no
significant differences between the pill and no pill subsets within
each treatment group.
contraceptive protects against the syndrome, even in
the epilepsy group, but that women taking valproate,
but not taking an oral contraceptive, are significantly
more likely to have the polycystic ovary syndrome.
An oral contraceptive does seem to protect against
the syndrome in the epilepsy group, but not signifi-
Table 3b:
N Testosterone FSH LH
VPA Pill 15 1.73 ± 1.18 4.29 ± 3.10 3.59 ± 3.27A
No pill 39 1.85 ± 0.66a,b 5.50 ± 2.01 6.67 ± 4.75A
LTG/CBZ Pill 14 1.20 ± 0.60 4.77 ± 1.74 4.95 ± 3.17
No pill 37 1.24 ± 0.51a,b,c 5.35 ± 2.13 5.01 ± 2.74
Normal Pill 23 1.67 ± 1.03 5.02 ± 3.03 2.74 ± 2.15B
No pill 27 1.86 ± 0.72a,c 4.96 ± 1.59 5.54 ± 2.90B
Between groups: aANOVA—P =< 0.001. Confirmed by Kruskal–Wallis. bVPA versus LTG/CBZ P =< 0.001 (t-test). cNormal versus
LTG/CBZ P = 0.001 (t-test). Within groups: AP = 0.026 (but not clinically significant and due to pill). BP =< 0.001 (again not
clinically significant and due to pill).
Table 3c:
N Testosterone FSH LH
Epilepsy 105 1.53 ± 0.76 5.18 ± 2.21 5.39 ± 3.80
Normal 50 1.77 ± 0.87 4.98 ± 2.34 4.25 ± 2.92
No significant differences between groups.
Table 3: Hormone levels.
Table 3a:
N Testosterone FSH LH
VPA 54 1.81 ± 0.83a ,b 5.16 ± 2.40 5.78 ± 4.56
LTG/CBZ 51 1.23 ± 0.53a ,b ,c 5.19 ± 2.03 4.99 ± 2.83
Normal 50 1.77 ± 0.87a ,c 4.98 ± 2.34 4.25 ± 2.92
a ANOVA—P =< 0.001. Confirmed by Kruskal–Wallis.
b VPA versus LTG/CBZ P =< 0.001 (t-test).
c Normal versus LTG/CBZ P = 0.001 (t-test).
cantly in the non-epilepsy group. The difference does
seem confined to the valproate non-pill group, and
strongly suggests that this group of patients is sig-
nificantly more likely to have the polycystic epilepsy
syndrome.
The overall biochemical effects are minimal
(Table 3a–d) and most are probably related to oral
contraceptive use but the group with clinical evidence
of the polycystic ovary syndrome is obviously differ-
ent in terms of the hormonal effect of the syndrome
(Table 3e).
Interestingly, the valproate polycystic ovary group
has abnormalities in both testosterone and LH levels;
the other polycystic ovary group in the normal pop-
ulation only significantly so in testosterone—but the
numbers are small (Table 3f).
The valproate group is slightly, but significantly
older than either of the other two groups (Table 4a
and b) (that are indistinguishable in terms of age).
When older and younger valproate group members
are compared, however (Tables 5 and 6) abnormal-
ities are only significant in the younger group. This
suggests that the effect of valproate in causing the
polycystic ovary syndrome may be confined to the
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Table 3d:
N Testosterone FSH LH
Epilepsy Pill 29 1.47 ± 0.97 4.52 ± 2.51 4.25 ± 3.24
No pill 76 1.55 ± 0.66a 5.43 ± 2.05 5.84 ± 3.94
Normal Pill 23 1.67 ± 1.03 5.02 ± 3.03 2.74 ± 2.15A
No pill 27 1.86 ± 0.72a 4.96 ± 1.59 5.54 ± 2.90A
Between groups: aP = 0.032 (t-test). Within groups: AP =< 0.001 (t-test).
Table 3e:
N Testosterone FSH LH
VPA Non-PCOS 38 1.48 ± 0.58a,b,A 5.18 ± 2.60 3.86 ± 2.22A
PCOS 16 2.60 ± 0.82∗,∗∗,A 5.13 ± 1.90 10.11 ± 5.52A
LTG/CBZ Non-PCOS 48 1.24 ± 0.54a,b,c 5.18 ± 2.07 4.57 ± 1.96B
PCOS 3 1.03 ± 0.40∗,∗∗,∗∗∗ 5.37 ± 1.46 11.73 ± 6.20B
Normal Non-PCOS 43 1.52 ± 0.47a,c,C 4.90 ± 2.41 3.97 ± 2.50
PCOS 7 3.33 ± 1.17∗,∗∗∗,C 5.51 ± 1.88 6.00 ± 4.67
Between groups: non-PCOS: aP = 0.026—ANOVA. Not confirmed by Kruskal–Wallis therefore is difference between the means but not
of significance. bP = 0.047 (t-test)—non-PCOS VPA versus LTG/CBZ. cP = 0.010 (t-test)—non-PCOS LTG/CBZ versus normal. PCOS:
∗P = 0.005—ANOVA. Confirmed by Kruskal–Wallis therefore significant. ∗∗P = 0.005 (t-test)—PCOS VPA versus LTG/CBZ.
∗∗∗P = 0.012 (t-test)—PCOS LTG/CBZ versus normal. Within groups: AVPA and testosterone P =< 0.001 (t-test) LH P =< 0.001
(t-test). BLTG/CBZ and LH P =< 0.001 (t-test). CNormal and testosterone P =< 0.001 (t-test).
Table 3f:
N Testosterone FSH LH
Epilepsy Non-PCOS 86 1.35 ± 0.56A 5.18 ± 2.30 4.27 ± 2.10B
PCOS 19 2.35 ± 0.96A 5.16 ± 1.80 10.36 ± 5.48B
Normal Non-PCOS 43 1.52 ± 0.47C 4.90 ± 2.41 3.97 ± 2.50
PCOS 7 3.33 ± 1.17C 5.51 ± 1.88 6.00 ± 4.67
Between groups: no significant differences between non-PCOS groups. No significant differences between PCOS groups. Within groups:
epilepsy group—Atestosterone P =< 0.001 (t-test). BLH P =< 0.001 (t-test). Normal group—Ctestosterone P =< 0.001 (t-test).
younger (particularly adolescent) patient, particularly
in those not taking the oral contraceptive.
Owing to an oversight not all weights and heights
were permanently recorded in the epilepsy group—but
the majority suggests that there was no great difference
Table 4: Age.
Table 4a:
N Testosterone
VPA 54 26.46 ± 6.72
LTG/CBZ 51 23.98 ± 5.86
Normal 50 22.46 ± 3.36
ANOVA between three groups P = 0.001 (t-test). VPA versus
normal P =< 0.001 (t-test). VPA versus LTG/CBZ not
significant. LTG/CBZ versus normal not significant.
Table 4b:
N Testosterone
Epilepsy 105 25.26 ± 6.41
Normal 50 22.46 ± 3.36
Between epilepsy and normal P = 0.004 (t-test).
in body mass index between the patients in the three
groups. If one wanted to be sure that a patient with
primary generalised epilepsy on valproate did not have
the polycystic ovary syndrome, it would be necessary
to measure LH, FSH, testosterone and prolactin at the
right time of the cycle.
In a group of young women therefore of whom 105
were taking, and had only ever taken, one antiepilep-
tic preparation (54 valproate, 51 lamotrigine (30) or
carbamazepine (21), and 50 who did not have epilepsy
Table 5: Normal ovaries versus PCO—age when AED
started.
N Normal % PCO %
(number) (number)
VPA <25 46 48 (22) 52 (24)
≥25 8 63 (5) 37 (3)
LTG/CBZ <25 46 65 (30) 35 (16)
≥25 5 80 (4) 20 (1)
Between treatment groups: <25 group no significant difference
between two treatment groups. ≥25 group no significant
difference between two treatment groups. Within treatment
groups: VPA, no significant difference between two age groups;
LTG/CBZ, no significant difference between two age groups.
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Table 6: Hormone levels—age when AED started.
N Testosterone FSH LH
VPA <25 46 1.92 ± 0.81 5.10 ± 2.40 6.11 ± 4.75
≥25 8 1.20 ± 0.68 5.55 ± 2.47 3.99 ± 2.92
LTG/CBZ <25 46 1.24 ± 0.53 5.13 ± 1.88 4.99 ± 2.93
≥25 5 1.10 ± 0.52 5.74 ± 3.36 4.98 ± 1.93
Between treatment groups: <25 group—testosterone
P =< 0.001 (t-test). FSH and LH—no significant difference
between treatment groups; ≥25 group—no significant difference
between two treatment groups. Within treatment groups: VPA,
testosterone P = 0.022 (t-test); FSH and LH—no significant
difference between two age groups; LTG/CBZ, no significant
difference between two age groups.
and who had never taken an anticonvulsant, some of
whom were taking an oral contraceptive and some
of whom were not, the only significant differences
were that women, especially younger women, taking
valproate and not taking an oral contraceptive were
significantly (P = 0.003) more likely to have the
polycystic ovary syndrome. All women with epilepsy,
if they were not taking the oral contraceptive, were
significantly more likely to have polycystic ovaries
than women who did not have epilepsy.
DISCUSSION
We have shown three things fairly convincingly.
The first is that women with epilepsy, particularly
if they are not taking an oral contraceptive, are more
likely than women who do not have epilepsy to have
polycystic (or polyfollicular) ovaries in the European
definition. Secondly, women with epilepsy who are
not taking an oral contraceptive are significantly more
likely to have the polycystic ovary syndrome if they
have only ever taken valproate (but not lamotrigine or
carbamazepine) (P = 0.003). This significance dis-
appears if women are taking the pill, suggesting as
our third finding that the oral contraceptive protects
against the polycystic ovary in women who take val-
proate as their anticonvulsant.
Thus we have partly (but not completely) proved
the findings of Isojärvi. Valproate would seem to, if
the oral contraceptive is not involved, significantly
increase the proportion of women with the polycys-
tic ovary syndrome (with impaired fertility and the
prospect, in later life, of possible diabetes and cancer
of the ovary3). If the woman is taking the oral con-
traceptive she is protected to a large extent against
the polycystic ovary syndrome, but obviously, whilst
taking the oral contraceptive will not get pregnant.
The reason why the polycystic ovary syndrome is sig-
nificantly commoner in women taking valproate as
their anticonvulsant probably is due to valproate be-
ing the only anticonvulsant to be associated with an
increase in insulin resistance, which is one of the
many factors to be associated with the polycystic ovary
syndrome3, 8.
This finding confirms our previous view3. Women
with epilepsy who wish sometime to become pregnant,
and most women do, should avoid valproate if at all
possible unless no other anticonvulsant will prevent
seizures. In women with primary generalised epilepsy
lamotrigine (or, sometimes, levetiracetam) is usually
an acceptable alternative or substitute. We will show,
in a separate later paper that 84% of women can be
successfully switched to lamotrigine from valproate
(and almost all the ones unsuccessful in that transition
can be transferred to levetiracetam). The transition is
a slow difficult one and it is better to start with lam-
otrigine if at all possible, rather than substitute later
(see Reference 12).
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